Charles River Laboratories International, Inc.
CRL
$178.14
-$0.80-0.45%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.42M | 52.33M | 25.47M | -214.50M | 69.66M |
| Total Depreciation and Amortization | 14.16M | 155.01M | 84.86M | 92.70M | 88.20M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 150.39M | -13.90M | 60.08M | 323.55M | 22.45M |
| Change in Net Operating Assets | -5.15M | 11.17M | 1.29M | -42.40M | 71.49M |
| Cash from Operations | 213.83M | 204.60M | 171.70M | 159.36M | 251.79M |
| Capital Expenditure | -35.58M | -35.30M | -59.32M | -75.62M | -38.72M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 0.00 | 0.00 |
| Divestitures | 0.00 | 0.00 | 17.44M | -- | -- |
| Other Investing Activities | 1.88M | -2.04M | -3.60M | -488.00K | 17.40M |
| Cash from Investing | -33.70M | -37.34M | -45.48M | -76.10M | -21.32M |
| Total Debt Issued | 107.50M | 547.02M | 416.34M | 104.80M | 235.58M |
| Total Debt Repaid | -253.79M | -738.31M | -149.39M | -176.78M | -329.65M |
| Issuance of Common Stock | 2.00K | 1.00K | -- | 768.00K | 779.00K |
| Repurchase of Common Stock | -93.00K | -7.35M | -353.13M | -124.00K | -100.79M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.23M | -28.28M | -19.14M | -4.54M | -13.47M |
| Cash from Financing | -152.62M | -226.92M | -105.33M | -75.88M | -207.54M |
| Foreign Exchange rate Adjustments | -3.03M | 12.67M | 5.27M | -13.45M | 7.70M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.48M | -46.99M | 26.16M | -6.07M | 30.64M |